TITLE: VAGUS NERVE STIMULATION

EFFECTIVE DATE: September 09, 2019

IMPORTANT INFORMATION – PLEASE READ BEFORE USING THIS POLICY

These services may or may not be covered by all Medica plans. Please refer to the member’s plan document for specific coverage information. If there is a difference between this general information and the member’s plan document, the member’s plan document will be used to determine coverage.

With respect to Medicare and Minnesota Health Care Programs, this policy will apply unless those programs require different coverage.

Medica may use tools developed by third parties, such as MCG Care Guidelines®, to assist in administering health benefits. Medica utilization management (UM) policies and MCG Care Guidelines are not intended to be used without the independent clinical judgment of a qualified health care provider taking into account the individual circumstances of each member’s case. Medica UM policies and MCG Care Guidelines do not constitute the practice of medicine or medical advice. The treating health care providers are solely responsible for diagnosis, treatment, and medical advice.

Members may contact Medica Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Medica UM policy may call the Medica Provider Service Center toll-free at 1-800-458-5512.

PURPOSE

To promote consistency between reviewers in utilization management decision-making by providing the criteria that generally determine the medical necessity of implantable vagus nerve stimulation. The Benefit Considerations box below outlines the process for addressing the needs of individuals who do not meet these criteria.

MEDICAL NECESSITY CRITERIA


BENEFIT CONSIDERATIONS

1. Prior authorization is required for initial implantation of a vagus nerve stimulator. Please see the prior authorization list for product specific prior authorization requirements.
2. Prior authorization is not required for reoperation/revision following implantation of a vagus nerve stimulator.
3. Implantable vagus nerve stimulation is investigative and therefore, not covered for all other indications not addressed in this policy, including but not limited to: Alzheimer’s disease, anxiety disorders, autism, bipolar disorders, bulimia, cerebral palsy, cluster headaches, depression, essential tremor, multiple sclerosis, fibromyalgia, heart failure, migraines, obesity, obsessive-compulsive disorder, post-traumatic stress disorder, sleep disorders, Tourette’s syndrome and traumatic brain injury.
4. Non-implantable transcutaneous vagus nerve stimulation (e.g., gammaCore®) is investigative and therefore not covered for all indications.
5. Coverage may vary according to the terms of the member’s plan document.
6. If the Medical Necessity and Coverage Criteria are met, Medica will authorize benefits within the limits in the member’s plan document.
7. If it appears that the Medical Necessity and Coverage Criteria are not met, the individual’s case will be reviewed by the medical director or an external reviewer. Practitioners are reminded of the appeals process in their Medica Provider Administrative Manual.
CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS)
• For Medicare members, refer to the following, as applicable at: http://www.cms.hhs.gov/mcd/search.asp?

**DOCUMENT HISTORY**

<table>
<thead>
<tr>
<th>Original Effective Date</th>
<th>July 1, 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>MPC Endorsement Date(s)</td>
<td>06/2014</td>
</tr>
<tr>
<td>Began use of MCG™ Care Guidelines</td>
<td>09/01/2015 (19th Edition)</td>
</tr>
<tr>
<td>Administrative Updates</td>
<td>05/01/2017, 04/18/2018</td>
</tr>
</tbody>
</table>